Vir Biotechnology (VIR) Accumulated Depreciation (2018 - 2023)

Vir Biotechnology (VIR) has 6 years of Accumulated Depreciation data on file, last reported at $26.2 million in Q1 2023.

• For the quarter ending Q1 2023, Accumulated Depreciation rose 65.06% year-over-year to $26.2 million; the trailing twelve-month figure through Mar 2023 stood at $26.2 million (up 65.06% YoY), and the FY2022 full-year result was $20.7 million, up 43.13% from the prior year.
• Accumulated Depreciation improved to $26.2 million in Q1 2023, from $20.7 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $26.2 million in Q1 2023 to a low of $4.2 million in Q3 2019.
• A 5-year average of $12.5 million and a median of $11.8 million in 2021 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation jumped 181.59% in 2019 and jumped 43.13% in 2022, its largest moves.
• Tracing VIR's Accumulated Depreciation over 5 years: stood at $4.8 million in 2019, then surged by 91.06% to $9.2 million in 2020, then jumped by 56.98% to $14.5 million in 2021, then surged by 43.13% to $20.7 million in 2022, then climbed by 26.54% to $26.2 million in 2023.
• Business Quant data shows VIR's Accumulated Depreciation at $26.2 million in Q1 2023, $20.7 million in Q4 2022, and $18.9 million in Q3 2022.